DHR

Integrated DNA Technologies Opens New Therapeutic Manufacturing Facility to Support Growing Demand in Genomic Medicine

Retrieved on: 
Tuesday, October 17, 2023
Science, Other Science, Biotechnology, Research, Health, Genetics, Clinical Trials, Other Health, Investment, Multimedia, DHR, Danaher Corporation, NYSE, ICH, Cas12a, Biology, Static pressure, Genome, Therapy, Integrated DNA Technologies, Temperature, ISO, CGMP, RUO, Humidity, ISO 8, Ultra, Documentation, Oligonucleotide, IDT, Drug discovery, Integration, RNA, Genomics, Danaher, HDR, Fine chemical, Medical device, CRISPR

Global genomics solutions provider Integrated DNA Technologies (IDT), an operating company in the Life Sciences segment of Danaher Corporation (NYSE:DHR), today announced the completion of its new Therapeutic Oligonucleotide Manufacturing facility in Coralville, Iowa.

Key Points: 
  • Global genomics solutions provider Integrated DNA Technologies (IDT), an operating company in the Life Sciences segment of Danaher Corporation (NYSE:DHR), today announced the completion of its new Therapeutic Oligonucleotide Manufacturing facility in Coralville, Iowa.
  • These new capabilities and offerings will be supported with comprehensive documentation and testing, a support team, and regulatory guidance to help accelerate researchers’ path to the clinic.
  • As a pioneer in genome editing, IDT’s continued investments will enable customers to rapidly move from clinical development to commercialization.
  • Mortenson Company, a team led by OPN Architects and Barr Engineering Co. on the facility design and construction of its cGMP facility.

Independent Directors of Abcam Highlight Compelling Reasons for Shareholders to Support Proposed Sale to Danaher

Retrieved on: 
Thursday, October 12, 2023
Professional Services, Health, Finance, Research, Science, Biotechnology, DHR, Danaher Corporation, NYSE, Human, BLUE, Lazard, LTM, Cyprus Securities and Exchange Commission, Transaction, Independent director, Morgan Stanley, Environment, Independent, Volume-weighted average price, Uncertainty, Volume, Discounted cash flow, Sale, Cryptocurrency, Management, Security (finance), Pharmaceutical industry, Auction, Risk management, Proxy, Abcam

We are writing to you today as the independent non-executive directors of Abcam’s Board of directors to affirm that this agreement was the result of a rigorous, fair and competitive sale process.

Key Points: 
  • We are writing to you today as the independent non-executive directors of Abcam’s Board of directors to affirm that this agreement was the result of a rigorous, fair and competitive sale process.
  • We unanimously support this Transaction as we believe it is the best deal available and is in the best interests of Abcam and its shareholders.
  • Ultimately, if this Transaction were not approved by shareholders, it is uncertain what path Abcam would be on next.
  • We need your support to secure a positive outcome for all Abcam shareholders.

ABCAM INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Abcam plc - ABCM

Retrieved on: 
Tuesday, October 10, 2023
Class Action Lawsuit, Professional Services, Legal, DHR, Danaher Corporation, NYSE, KSF, Sale, Abcam

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Abcam plc (NasdaqGS: ABCM) to Danaher Corporation (NYSE: DHR).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Abcam plc (NasdaqGS: ABCM) to Danaher Corporation (NYSE: DHR).
  • Under the terms of the proposed transaction, shareholders of Abcam will receive $24.00 in cash for each share of Abcam that they own.
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

Molecular Devices Introduces CellXpress.ai Automated Cell Culture System, a 3D Biology Innovation Hub for Fast, Reliable Drug Discoveries

Retrieved on: 
Monday, October 16, 2023
Algorithm, Partnership, DHR, Danaher Corporation, NYSE, 3D, Drug development, Intelligence, Automation, Completeness, AI, Therapy, Society, 2D, Molecular Devices, SAN, Drug discovery, Cardioid, Conference, Informatics, Fine chemical

SAN JOSE, Calif., Oct. 16, 2023 /PRNewswire-PRWeb/ -- Molecular Devices, LLC., a leading high-performance life science solutions provider and an operating company in the life sciences segment of Danaher Corporation (NYSE:DHR), has launched the CellXpress.ai™ Automated Cell Culture System—an end-to-end, machine learning-enabled solution that automates demanding feeding and passaging schedules with an integrated incubator, liquid handler, and imager, giving scientists more time and autonomy in the lab. The visionary goal for this instrument is to reduce reliance on animal models in drug development while enhancing productivity, optimizing efficiency, and fast-tracking potential therapeutics to pre-clinical trials using human-relevant models earlier in the process.

Key Points: 
  • "In drug discovery, we recognize the significance of having advanced cell culture protocols for 3D biology models," said Shantanu Dhamija, Vice President of Strategy and Innovation Molecular Devices.
  • Key features of the CellXpress.ai cell culture system include:
    Reduce Labor Costs: Until now, large-scale cell culture has demanded round-the-clock oversight.
  • The CellXpress.ai cell culture system uses automation and AI to maintain this 24/7 schedule, improving workflows and making assays more reliable and reproducible.
  • To learn more or to join a community of researchers at the forefront of innovation using the CellXpress.ai cell culture system, visit CellXpressAI.com .

Abcam Files and Mails Scheme Circular Seeking Approval of Acquisition of Abcam by Danaher for $24.00 per Share

Retrieved on: 
Thursday, October 5, 2023
Research, Technology, Medical Devices, Finance, Other Technology, Health Technology, Professional Services, Biotechnology, Health, Science, DHR, NYSE, Mass meeting, Acquisition, Morgan Stanley, Annual general meeting, Shareholder Meeting, Lazard, BLUE, High court, Court, Transaction, Proxy, CREST, Volume-weighted average price, Citibank, Sale, Youth justice in England and Wales, Volume, YELLOW, Cryptocurrency, Security (finance), Auction, Management, Equiniti, Abcam

Under the terms of the Transaction Agreement, Danaher will acquire all of the outstanding shares of Abcam for $24.00 per share in cash.

Key Points: 
  • Under the terms of the Transaction Agreement, Danaher will acquire all of the outstanding shares of Abcam for $24.00 per share in cash.
  • Highlights from the Scheme Circular include:
    The Transaction delivers significant, certain, and immediate value to shareholders.
  • Abcam received multiple bids to acquire the Company, rejected bids it deemed inadequate, and structured a process that induced bidders to increase offers.
  • Danaher’s $24.00 per share in cash offer was the highest and best price received at any point in the process.

Remedios Varo Exhibition at Art Institute of Chicago Celebrates Hispanic Heritage Through Art

Retrieved on: 
Monday, October 2, 2023
Science, Exhibition, Culture, World Business Chicago, Hope, National Hispanic Heritage Month (United States), Woman, DHR, Art Institute, Art, Art Institute of Chicago, Edelman, DEI, Jesse Jackson, Nightclub

CHICAGO, Oct. 2, 2023 /PRNewswire/ -- The Art Institute of Chicago came alive with the celebration of Hispanic Heritage Month hosted by We Are All Human Foundation (WAAH), a leading global nonprofit dedicated to advancing diversity, equity, and inclusion (DEI). The event, "Discovering Hispanic Contributions to America through Art: Remedios Varo: Science Fictions," drew over 60 leaders from various industries to explore the rich and vibrant legacy of the Hispanic community in the United States. The gathering was marked by the presence of Reverend Jesse Jackson, a renowned civil rights leader, who shared a powerful message of unity and appreciation for the Hispanic community's invaluable contributions.

Key Points: 
  • The event, "Discovering Hispanic Contributions to America through Art: Remedios Varo: Science Fictions," drew over 60 leaders from various industries to explore the rich and vibrant legacy of the Hispanic community in the United States.
  • The night was centered around the "Remedios Varo: Science Fictions" exhibition at The Art Institute of Chicago, offering attendees the opportunity to immerse themselves in the world of Hispanic art.
  • This exhibition marks the first US exhibition on Remedios Varo since 2000 and a rare exhibition at the Art Institute to offer gallery text in both Spanish and English.
  • He stated, "I am honored to celebrate the invaluable contributions of Latinos to the country during this Hispanic Heritage Month.

Lifshitz Law PLLC Announces Investigations of Integra LifeSciences Holdings Corporation (NASDAQ: IART), Enviva, Inc. (NYSE: EVA), and DitigialOcean Holdings, Inc. (NYSE: DOCN), and Danaher Corp. (NYSE: DHR)

Retrieved on: 
Sunday, October 1, 2023
Telephone, COVID-19, Danaher, Integra, Lipopolysaccharide, Boston, DHR, EVA, Advertising, Growth, FDA, Hewlett, Cryptocurrency, Pharmaceutical industry, Online shopping

The Company also extended the pause on all production at the Boston Facility.

Key Points: 
  • The Company also extended the pause on all production at the Boston Facility.
  • The Company further disclosed that it expected to take a $22 million impairment charge in the second quarter due to the inventory write-off.
  • These disclosures caused the price of Integra stock to decline by an additional $10.24 per share, or 20%.
  • The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780.

Battery Ventures Creates Latest Lab-Automation Technologies Platform with Investments in Skalar Analytical, PromoChrom and LCTech

Retrieved on: 
Thursday, September 28, 2023
Technology, Professional Services, Food, Beverage, Agriculture, Natural Resources, Apps, Applications, Retail, Software, Environment, Food Tech, Finance, SPE, Ingersoll Rand, Partnership, PFAS, Overalls, DHR, Amod, Chemistry, Investment, Battery, Growth, Robotics, Battery Ventures, NYSE, Automation, Fine chemical

Battery Ventures, a global, technology-focused investment firm, today announced the creation of a new laboratory-automation platform following recent acquisitions of three complementary companies: Skalar Analytical, PromoChrom Technologies and LCTech.

Key Points: 
  • Battery Ventures, a global, technology-focused investment firm, today announced the creation of a new laboratory-automation platform following recent acquisitions of three complementary companies: Skalar Analytical, PromoChrom Technologies and LCTech.
  • Skalar Analytical, based in Breda, the Netherlands, manufactures a range of chemistry analyzers and laboratory-automation solutions for environmental and agricultural applications.
  • The selling shareholder group from Skalar Analytical, led by Rene van der Wagt and Sjaak Furrer, were pleased to partner with Battery to help take Skalar to the next level.
  • “Today, we embark on an exciting new chapter as we join forces with like-minded individuals at Skalar and Battery.

Jonathan Milner issues Open Letter to shareholders of Abcam plc

Retrieved on: 
Thursday, September 28, 2023
Uncertainty, Heart, LSE, Maintenance, London Stock Exchange, ALL, COST, Non-executive director, Autumn, Mass meeting, EGM, Main–Market Historic District, DHR, Antibody, Sale, Depression, EBITDA, Acquisition, Accounting, CFO, FORM, BOARD, Empathy, WITH, Letter, NYSE, Chair, Cryptocurrency, Management, Abcam

I sought to rejoin the Board with the intention of leveraging my experience and expertise to help steer Abcam back to its previous fortunes.

Key Points: 
  • I sought to rejoin the Board with the intention of leveraging my experience and expertise to help steer Abcam back to its previous fortunes.
  • I believe that this offer grossly undervalues Abcam, confirming my doubts about the Board’s commitment to securing the best deal for shareholders.
  • Abcam also benefitted from a scarcity value when listed in London with a broad and deep following of long-standing institutional shareholders.
  • I encourage shareholders to visit my website for further details of my campaign and to see updates on my plan for Abcam.

Danaher Schedules Third Quarter 2023 Earnings Conference Call

Retrieved on: 
Tuesday, September 26, 2023
Danaher Corporation, Webcast, Danaher, DHR, Conference, NYSE

WASHINGTON, Sept. 26, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2023 on Tuesday, October 24, 2023 beginning at 8:00 a.m.

Key Points: 
  • WASHINGTON, Sept. 26, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2023 on Tuesday, October 24, 2023 beginning at 8:00 a.m.
  • ET and notifying the operator that you are dialing in for Danaher's earnings conference call (Conference ID: DHRQ323).
  • A replay of the conference call will be available shortly after the conclusion of the call until November 8, 2023.
  • Danaher's earnings press release, the webcast slides and other related materials will be posted to the "Investors" section of Danaher's website under the subheading "Quarterly Earnings" beginning at 6:00 a.m.